Antitumoral effect of phenazine N5,N10-dioxide derivatives on Caco-2 cells

Chemical Research in Toxicology

Volumn 21, Issue 8, 2008, Pages 1578-1585

  Pachón, Olga Gisela ^a   Azqueta, Amaia ^b   Lavaggi, Maria Laura ^c   De Cerain, Adela López ^b   Creppy, Edmond ^d   Collins, Andrew ^e   Cerecetto, Hugo ^c   González, Mercedes ^c   Centelles, Josep Joan ^a   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7(8) ( 1,3 DIOXOL 2 YL)PHENAZINE N5,N10 DIOXIDE; 2 AMINO 7(8) METHOXYPHENAZINE N5,N10 DIOXIDE; 2 CHLOROACETYLAMINO 7 (8) NITROPHENAZINE N5,N10 DIOXIDE; 2 CHLOROACETYLAMINO 7(8) (1,3 DIOXOL 2 YL )PHENAZINE N5,N10 DIOXIDE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYTOCHROME C; OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFECT; GENOTOXICITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; NONHUMAN;

EID: 51449111023     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800032k     Document Type: Article

References (27)

1. Lin, A. J., Cosby, L. A., Shansky, C. W., and Sartorelli, A. C. (1972) Potential bioreductive alkylating agents 1. Benzoquinones derivatives. J. Med. Chem. 15, 1247-1252.
2. Denny, W. A. (2000) The role of hypoxia.activated.prodrugs in cancer merapy. Oncology 1, 25-29.
3. Rauth, A. M., Melo, T., and Mishra, V. (1998) Bioreductive therapies: An overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42, 755-762.
4. Denny, W. A. (2001) Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577-595.
5. Wouters, B. G., Weppler, S. A., Koritzinsky, M., Landuyt, W., Nuyts, S., and Theys, J. (2002) Hypoxia as a target for combined modality treatments. Eur. J. Cancer. 38, 240-257.
6. Cerecetto, H., González, M., Lavaggi, M. L., Aravena, M. A., Rigol, C., and Olea-Azar, C. (2006) Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins: Part II. Structure-activity relationship studies. Med Chem. 2, 511-521.
7. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. (1986) SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol., Biol., Phys. 12, 1239-1242.
8. Elwel, J. H., Siim, B. G., Evans, J. W., and Brown, J. M. (1997) Adaptation of human tumour cells to tirapazamine under aerobic conditions - Implications of increased antioxidant enzyme activity to mechanism of aerobic toxicity. Biochem. Pharmacol. 54, 249-257.
9. Brown, J., and Wiliam, R. (2004) Exploiting tumour hypoxia in cancer treatment. Nat. Rev. 4, 437-447.
10. Cerecetto, H., and González, M. (2001) N-Oxides as hypoxia selective cytotoxins. Mini Rev. Med. Chem. 1, 219-231.
11. Anderson, R. F., Harris, T. A., Hay, M. P., and Denny, W. A. (2003) Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamine. Chem. Res. Toxicol. 16, 1477-1483.
12. Anderson, R. F., Shinde, S. S., Hay, M. P., Gamage, S. A., and Denny, W. A. (2003) Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. Org. Biomol. Chem. 3, 2167-2174.
13. Delahoussaye, Y. M., Hay, M. P., Pruijn, F. B., Denny, W. A., and Brown, J. M. (2003) Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol 65, 1807-1815.
14. Kovacs, M. S., Hocking, D. J., Evans, J. W, Siim, B. G., Wouters, B. G., and Brown, J. M. (1999) Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 80, 1245-1251.
15. Von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., and Clark, P. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18, 1351-1359.
16. Patterson, H. L. (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Met. Rev. 12, 119-134.
17. Lee, H. H., Wilson, W. R., Ferry, D. M., Van Zijl, P., Pullen, S. M., and Denny, W. A. (1996) Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J. Med. Chem. 39, 2508-2517.
18. Monge, A., Palop, J. A., López de Cerain, A., Senador, V., Martínez-Crespo, F. J., and Sainz, P. (1995) Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem. 38, 1786-1792.
19. Boiani, M., Cerecetto, H., González, M., Risso, M., Olea-Azar, C., and Piro, O. E. (2001) 1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: Synthesis and biological evaluation. Part IV. Eur. J. Med Chem. 36, 771-782.
20. Boiani, M., Cerecetto, H., González, M., Piro, O. E., and Castellano, E. (2004) Tautomerism and reactivity in heterocyclic N-oxides. A spectroscopic and theorical study of benzimidazole N-oxide derivatives (N-hydroxybenzimidazoles). J. Phys. Chem. A 108, 11241-11248.
21. Cerecetto, H., González, M., Onetto, S., Saenz, P., Ezpeleta, O., and De.Ceráin, A. L. (2004) 1,2,4-Triazine N-oxide derivatives: Studies as potential hypoxic cytotoxins. Part II. Arch. Pharm. (Weinheim, Ger.) 337, 247-258.
22. Cerecetto, H., Gonzalez, M., Lavaggi, M. L., Azqueta, A., Lopez de.Cerain, A., and Monge, A. (2005) Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins. J. Med. Chem. 48, 21-23.
23. 10-dioxide via expansion process with phenolates. J. Braz. Chem. Soc. 6, 1290-1296.
24. Mossman, B. T. (1983) In vitro approaches for determining mechanisms of toxicity and carcinogenicity by asbestos in the gastrointestinal and respiratory tracts. Environ. Health Perspect. 53, 151-161.
25. Lozano, C., Torres, J. L., Julia, L., Jimenez, A., Centelles, J. J., and Cascante, M. (2005) Effect of a new antioxidant cysteynil-flavanol conjugates on skin cancer cells. FEBS Lett. 579, 4219-4225.
26. Singh, N. P., McCoy, M. T., Tice, R. R., and Schneider, E. L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175, 184-191.
27. Tice, R. R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., Miyamae, Y., Rojas, E., Ryu, J. C., and Sasaki, Y. F. (2000) Single cell gel/Comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutatagen. 35, 206-221.